Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Last trade$3.12
Day change-$0.005 (-0.16%)
Day range$3.00 – $3.63
Volume296,711
Market cap$141M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$141.13M
Price / earnings
—
Price / book
0.59×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.48×
Profitability
Earnings per share
-$2.42
Return on assets
-41.6%
Return on equity
-45.54%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
13.92×
Quick ratio
13.92×
Cash ratio
5.11×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$79.61M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SION, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Revenue
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$12.79M
$10.61M
$10.64M
$8.44M
$7.76M
$6.52M
$5.99M
Research and development
$22.03M
$21.86M
$18.96M
$15.17M
$16.04M
$15.38M
$13.67M
Total operating expenses
$34.83M
$32.47M
$29.6M
$23.61M
$23.73M
$21.74M
$19.66M
Operating income
-$34.83M
-$32.47M
-$29.6M
-$23.61M
-$23.73M
-$21.74M
-$19.66M
Interest expense
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$32.42M
-$29.89M
-$26.78M
-$20.44M
-$20.28M
-$18.07M
-$16.48M
Income taxes
$0
$0
$0
$0
$0
$0
$0
Net income
-$32.42M
-$29.89M
-$26.78M
-$20.44M
-$20.28M
-$18.07M
-$16.48M
Net income attributable to common shareholders
-$32.42M
-$29.89M
-$26.78M
-$20.44M
-$20.28M
-$18.07M
-$16.48M
EBITDA
-$34.67M
-$32.32M
-$29.45M
-$23.46M
-$23.55M
-$21.59M
-$19.5M
Basic earnings per share
-$0.72
-$0.66
-$0.60
-$0.46
-$0.46
-$0.41
-$0.62
Diluted earnings per share
-$0.72
-$0.66
-$0.60
-$0.46
-$0.46
-$0.41
-$0.62
Recent news
Company coverage with links to the original publishers.
Sionna Therapeutics announced it will advance its SION-451 + SION-2222 dual combination into the AscenSION CF Phase 2 proof-of-concept trial, expected to initiate in Q1 2027. The company reported a strong cash position of $249.8 million as of September 30, 2026, expected to fund operations into the second half of 2029. However, the company implemented a 46% workforce reduction in September 2026 to focus resources on the dual combination program and extend its operating runway.
Sionna Therapeutics announced it will participate in investor conferences and present data at the 2026 North American Cystic Fibrosis Conference. Post hoc analyses of SION-719 showed promising results with mean placebo-adjusted sweat chloride reduction of up to -8.6 mmol/L, supporting advancement of the dual combination SION-451 + SION-2222 into Phase 2a proof-of-concept trial.
Pomerantz LLP is investigating potential securities fraud claims against Sionna Therapeutics following the company's August 10, 2026 announcement that its PreciSION CF Phase 2a trial failed to achieve its key activity endpoint. The failure to demonstrate efficacy of SION-719 when combined with Trikafta resulted in a dramatic 91.18% stock price decline, falling from approximately $51.04 to $4.50 per share.
Sionna Therapeutics announced a 46% workforce reduction and major restructuring following the failure of SION-719 to meet its primary endpoint in a cystic fibrosis study. The company is shifting focus to its dual combination therapy SION-451 + SION-2222, which it plans to advance into phase IIa trials in 2027. The restructuring is expected to extend cash runway into the second half of 2029.
Law firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.